AI identifikasi obat kanker payudara untuk berbagai virus

Jumat, 03 April 2026

Dilaporkan oleh AI

Obat kanker payudara yang dialihfungsikan bernama MDL-001 telah menunjukkan potensi dalam studi laboratorium dan hewan terhadap berbagai virus, termasuk flu, covid-19, RSV, dan norovirus. Dikembangkan oleh Model Medicines yang berbasis di California menggunakan AI, pil ini menargetkan domain enzim yang terkonservasi pada virus. Uji klinis direncanakan akan dilakukan awal tahun depan.

Model Medicines, sebuah perusahaan asal California, telah mengalihfungsikan obat kanker payudara yang sempat dihentikan pengembangannya, yaitu ERA-923, yang kini dinamai ulang menjadi MDL-001, untuk melawan berbagai jenis virus. Salah satu pendiri, Daniel Haders, menyatakan, “Sejauh yang kami ketahui, ini adalah obat pertama yang pernah menunjukkan aktivitas di seluruh keluarga virus ini.” Platform AI tersebut mengidentifikasi potensi obat ini untuk mengikat domain Thumb-1 dari RNA-dependent RNA polymerase, sebuah situs terkonservasi pada virus yang membantu replikasi. Haders menjelaskan, “Kami ingin menemukan titik kritis biologis – tempat di mana satu obat terhadap satu target dapat menyelesaikan masalah puluhan penyakit.”

DNA origami “DoriVac” shows strong immune activation in early tests, offering a potential complement to mRNA vaccines

Selasa, 17 Maret 2026 Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

Researchers at Harvard’s Wyss Institute and Dana-Farber Cancer Institute report that a DNA origami-based vaccine platform called DoriVac generated robust immune responses in mice and in a human lymph node “Organ Chip” model. The team says the approach could be easier to store and manufacture than lipid nanoparticle–delivered mRNA vaccines, though the work remains preclinical. The results were published in Nature Biomedical Engineering.

Stanford scientists develop universal nasal spray vaccine

Researchers at Stanford Medicine have created an experimental nasal spray vaccine that protects mice against multiple respiratory threats, including COVID-19, flu, bacterial pneumonia, and allergens. The vaccine activates the lungs' innate immune system for months, offering broad defense without targeting specific pathogens. Published in Science on February 19, the study suggests potential for human trials soon.

RSV infection in mice prevents breast cancer spread to lungs

Jumat, 24 April 2026 Dilaporkan oleh AI

Researchers found that infecting mice with respiratory syncytial virus (RSV) reduced breast cancer cells' ability to form tumors in the lungs by 65 to 70 percent. The effect stems from type I interferons, proteins that fight viral replication and hinder cancer cell seeding. The study raises hopes for drugs mimicking this mechanism.

Kesehatan

Scientists engineer probiotic bacteria to target mouse tumors

Kesehatan

Scientists develop molecule to target aggressive breast cancer

Kesehatan

Scientists develop antibodies to block widespread Epstein-Barr virus

Virus therapy enhances immune attack on glioblastoma

Researchers report that a single injection of a modified herpes virus draws immune cells deep into glioblastoma tumors, leading to longer survival in a clinical trial. The therapy, tested on 41 patients with recurrent brain cancer, activates T cells that persist and attack cancer cells. Findings were published in Cell.

Engineered antibody shrinks tumors body-wide in early cancer trial

Senin, 16 Maret 2026 Dilaporkan oleh AI

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.

11 Mei 2026 03.38